Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Cash from Operations: 2012-2024

Historic Cash from Operations for Ultragenyx Pharmaceutical (RARE) over the last 13 years, with Dec 2024 value amounting to -$414.2 million.

  • Ultragenyx Pharmaceutical's Cash from Operations fell 36.46% to -$91.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$445.7 million, marking a year-over-year decrease of 6.47%. This contributed to the annual value of -$414.2 million for FY2024, which is 12.77% up from last year.
  • As of FY2024, Ultragenyx Pharmaceutical's Cash from Operations stood at -$414.2 million, which was up 12.77% from -$474.8 million recorded in FY2023.
  • Ultragenyx Pharmaceutical's 5-year Cash from Operations high stood at -$132.2 million for FY2020, and its period low was -$474.8 million during FY2023.
  • Over the past 3 years, Ultragenyx Pharmaceutical's median Cash from Operations value was -$414.2 million (recorded in 2024), while the average stood at -$423.2 million.
  • In the last 5 years, Ultragenyx Pharmaceutical's Cash from Operations soared by 61.72% in 2020 and then plummeted by 156.16% in 2021.
  • Ultragenyx Pharmaceutical's Cash from Operations (Yearly) stood at -$132.2 million in 2020, then tumbled by 156.16% to -$338.7 million in 2021, then decreased by 12.33% to -$380.5 million in 2022, then dropped by 24.80% to -$474.8 million in 2023, then increased by 12.77% to -$414.2 million in 2024.